Posted by Michael Wonder on 26 Aug 2025
European Commission authorises twice yearly Yeytuo (lenacapavir) for HIV prevention
26 August 2025 - Accelerated EC decision comes after US FDA approval in June.
Gilead Sciences today announced that the European Commission has granted marketing authorisation for Yeytuo (lenacapavir)—the company’s twice yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35 kg.
